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[57] ABSTRACT 
The invention provides a novel method of administer 
ing narcotic antagonists, narcotic analgesics and related 
compounds, and novel dosage forms containing those 
compounds which are adapted for nasal administration. 
The nasal dosage forms disclosed include solutions, 
suspensions, gels and ointments. Especially preferred 
compounds which can be advantageously administered 
in accordance with the invention include naloxone, 
naltrexone, nalbuphine, levorphanol, buprenorphine, 
butorphanol, A9-tetrahydrocannabin0l (THC), can 
nabidiol (CBD) and levonantradol. 
51 Claims, 1 Drawing Figure 
4,464,378 Aug. 7, 1984 ' US. Patent 
rlllAlull 1 
25$ 453% §$‘$5
160 
l 
120 
4,464,378 
1 
METHOD OF ADMINISTERING NARCOTIC 
ANTAGONISTS AND ANALGESICS AND NOVEL 
DOSAGE FORMS CONTAINING SAME 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to a novel method of 
administering narcotic antagonists, narcotic analgesics 
and related compounds, and to novel dosage forms 
containing such compounds adapted for nasal adminis 
tration. ‘ 
2. Background Art 
Morphine, which has the structural formula 
N-Cl-Ig 
> 
' HO O on 
is a potent narcotic analgesic which is principally used 
to relieve pain; it is also used in the dyspnea of heart 
failure, in pulmonary edema and cough, as a sedative 
and in the control of diarrhea (chiefly in the form of 
paragoric). Morphine causes both depression and stimu 
lation in the central nervous system and the gut, its most 
signi?cant actions being analgesia, hypnosis, respiratory 
depression, smooth muscle spasm, nausea, vomiting and 
circulatory and other effects (especially miosis). The 
drug is well-absorbed by injection, but absorption via 
the oral route is inefficient and variable, probably be 
cause of metabolismiinthe liver, chie?y by conjugation 
with glucuronic acid. Abuse leads to habituation or 
addiction. 
The morphine molecule has been subjected to a vari 
ety of structural modi?cations in efforts to enhance 
selected properties and/or to deemphasize others, as 
well as to produce-drugs which actually antagonize the 
effects of morphine and other opioid analgesics. Such 
efforts have led to the development of a variety of 
classes of chemical compounds, such as the class of 
morphine analogues whose structures are very closely 
allied to that of morphine, retaining both the phenolic 
OH and the N-methyl substituent of morphine, such as 
apomorphine, levorphanol and oxymorphone, and 
which as a group have strong analgesic, respiratory 
depressant and smooth muscle stimulant activity but 
which also are highly addicting. Retention of the phe 
nolic hydroxyl while replacing the methyl on the nitro 
gen atom with a larger alkyl or similar side-chain has 
afforded both morphine analogues which are relatively 
pure opioid antagonists (e.g. naloxone and naltrexone) 
and‘are used in the treatment of narcotic-induced respi 
ratory depression (overdose), in the diagnosis of nar 
cotic addiction and in the prophylaxis of narcotic abuse; 
and morphine analogues which are agonist-antagonists 
(e.g. buprenorphine, pentazocine, nalorphine and cy 
clazocine), which display varying degrees of morphine 
like activity as well as of morphine-antagonist behavior, 
and which can therefore be used as analgesics as well as 
for the purposes for which the relatively pure antago 
nists are used. Buprenorphine appears to be a particu 
larly valuable analogue because of its low physical de 
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pendence potential, as well as its potent narcotic .antag 
onist and analgesic activity. See Cowan et al, Br. J. 
Pharmac. (1977), 60, 537-545; Jasinski et al, Arch. Gen. 
Psychiatry, Vol. 35, April 1978, 501-516; Mello et al, 
Science, Vol. 207, Feb. 8, 1980, 657-659. 
Virtually all of the members of the groups of mor 
phine analogues discussed supra are well-absorbed by 
injection, but are rarely used orally because of inef? 
cient and variable absorption by that route. The low 
effectiveness of naloxone when taken orally has been 
attributed to the rapid and almost total formation of a 
less activemetabolite in the ?rst hepatic transit. See 
Fishman et al, J. Pharmacol. Exp. T her. 187, 575-580 
(1973). Also Berkowitz et al, J. Pharmacol. Exp. Ther. 
195, 499-504, and the references cited therein. 
Yet other structural modi?cations of the morphine 
molecule have resulted in codeine and its analogues; 
methadone and related compounds; and meperidine and 
related compounds such as profadol. Also see, gener 
ally, Pharmacological Basis of Therapeutics, ed. Good 
man and Gilman, sixth edition, Chapter 22, “Opioid 
Analgesics and Antagonists”, by Jaffe and Martin, pp. 
494-534 (MACMILLAN PUBLISHING CO., INC., 
New York, 1980); Cutting’s Handbook of Pharmacology, 
sixth edition, ed. T. Z. Czaky, M.D., Appleton-Cen 
tury-Crofts/New York, Chapter 50, pp. 551-571. 
Recent studies of THC, or A9-tetrahydrocannabinol, 
which is the active ingredient in marijuana, or its deriv 
atives (e.g. CBD or cannabidiol, and levonantradol) 
suggest that these compounds are potentially useful in a 
wide varietyvof therapeutic areas, such as in the preven 
tion of narcotic withdrawal symptoms and as antiemet 
ics, particularly in the treatment of cancer patients un 
dergoing chemotherapy. Unfortunately, oral adminis 
tration has been found to be much less effective than 
intramuscular injection. See, Medical News, Monday, 
Jan. 19, 1981, page 3, for a more detailed discussion of 
the various therapeutic uses of THC and its derivatives. 
SUMMARY OF THE INVENTION 
‘In view of the foregoing, it is apparent that a serious 
need exists for the improved delivery of narcotic antag 
onists‘, narcotic analgesics and related compounds 
which are not well-absorbed orally. Thus, it is an object 
of the present invention to provide novel dosage forms 
and a novel method of administering morphine or an 
analogue thereof bearing at least one phenolic hydroxyl 
substituent and having narcotic analgesic, antagonist or 
agonist-antagonist activity, or A9-tetrahydrocannabino1 
or a pharmacologically active analogue thereof bearing 
at least one phenolic hydroxyl substituent, which will 
provide greatly enhanced bioavailability as compared 
to oral administration, while at the same time providing 
- relative ease of administration when compared to intra 
muscular, subcutaneous or intravenous injection. This 
object is achieved by nasal administration of morphine, 
A9-tetrahydrocannabinol, or one of their aforesaid phe 
nolic, pharmacologically active analogues, advanta 
geously formulated into a solution, suspension, ointment 
or gel adapted for nasal administration. ' 
BRIEF DESCRIPTION OF THE DRAWING 
The FIGURE of the drawing is a semi-logarithmic 
plot of mean plasma levels of naloxone after intrave 
nous, nasal and oral administration of a dose of 30 pg of 
naloxone per rat. 
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DETAILED DESCRIPTION OF THE 
INVENTION 
The narcotic analgesics, narcotic antagonists and 
narcotic agonist-antagonists intended for use in the 
compositions and method of the present invention in 
clude morphine and pharmacologically active ana 
logues thereof having at least one aromatic ring, said 
ring bearing at least one free OH group. Particularly 
signi?cant morphine analogues contemplated by the 
present invention include morphine-like analgesics such 
as apomorphine, hydromorphone, levorphanol, meto 
pon and oxymorphone; and narcotic antagonists and 
agonist-antagonists such as buprenorphine, diprenor 
phine, butorphanol, cyclazocine, pentazocine, phenazo 
cine, levallorphan, nalorphine, naloxone, alazocine, 
nalbuphine, oxilorphan, nalmexone and naltrexone. 
Other analogues contemplated by the invention in 
cluded ketobemidone, apocodeine, profadol, cyclor 
phan, cyprenorphine, desomorphine, dihydromorphine, 
3-hydroxy-N-methylmorphinan, levophenacylmor 
phan, metazocine, norlevorphanol, oxymorphone, 
phenomorphan, pholcodine and hydroxypethidine. Es 
pecially preferred morphine analogues are those having 
antagonist or agonist-antagonist properties, especially 
naloxone, nalbuphine, naltrexone, buprenorphine and 
butorphanol. Any pharmaceutically acceptable form of 
morphine or of its phenolic analogues can be used, i.e. 
the free base or a pharmaceutically acceptable acid 
addition salt thereof (e. g. naloxone hydrochloride, nal 
buphine hydrochloride, nalorphine hydrochloride, na 
lorphine hydrobromide, levallorphan tartrate, mor 
phinc sulfate, levorphanol tartrate, buprenorphine hy 
drochloride, butorphanol tartrate, pentazocine lactate, 
pentazocine hydrochloride, phenazocine hydrobro 
mide, morphine hydrochloride, profadol hydrochlo 
ride, etc.); generally, the selected compound is em 
ployed in the instant compositions and method in the 
pharmaceutically acceptable form which has previously 
been found most advantageous for use by injection or 
orally. The structural formulae for representative free 
bases encompassed by the present invention are set 
forth below: 
apomorphine 
HO OH 
levorphano] 
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-continued 
profadol OH 
N 
These morphine analogues and their salts can be pre 
pared by well-known methods. Morphine itself can of 
course be isolated from natural ‘sources and then con 
verted, if desired, into a pharmaceutically acceptable 
acid addition salt. » 
The cannabinoids intended for use in the method and 
compositions of the present invention include A9-tet 
rahydrocannabinol (THC) and pharmacologically ac 
tivederivatives thereof having at least one free OH 
group on an aromatic ring thereof. .A9-Tetrahydrocan 
nabinol has the structural formula 
Preferred derivatives thereof for use in the present in 
vention include‘cannabidiol (CBD) and levonantradol. 
These compounds can be prepared by known methods 
or, in the case of THC and CBD, isolated from natural 
sources. ' ' ' 
In accord with the present invention, morphine, THC 
and‘ their pharmacologically active phenolic analogues 
can be administered nasally with results considerably 
superior to those obtained with oral administration in 
terms of enhanced drug bioavailability and minimiza 
tion of blood level variations, thus enabling 'use of these 
drugs at the dosage levels previously possible only by ‘ 
injection without the disadvantages inherent in subcuta- “ 
neous, intrasmuscular or intravenous administration. It 
would appear that‘ these drugs are rapidly absorbed 
from the nasal mucosa into systemic blood without 
extensive metabolism in the gastrointestinal tract and 
./or extensive ?rst-pass metabolism. 
The following study was undertaken to examine the 
bioavailability of a representative drug employed in the 
method and compositions of the invention, namely nal 
oxone, administered nasally, in comparison with the 
‘bioavailability of that drug when administered orally 
and intraveneously. 
Sprague-Dawley male rats, each weighing about 270 
grams, were used in the study. Three groups of three, 
rats each were employed, one group for each route of 
administration. The rats were anesthetized with pento 
barbital (50 mg/kg) prior to administration of the drug. 
Naloxone was administered at a dose of 30 lag/rat (~40 
pCi/rat) as 3H-naloxone in 0.1 m1 of isotonic saline. For 
intravenous administration, the drug was injected 
' through the femoral vein. For oral (intraduodenal) ad 
ministration, the abdomen of ‘ each rat was opened 
through a midline incision and the drug was injected 
4,464,378 
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directly through the duodenum. For nasal administra 
tion, an incision was made in the neck of each rat and 
the trachea was cannulated with a polyethylene tube. 
Another tube was inserted from the esophagus to the 
posterior part of the nasal cavity, and the nasoplantine 
was closed with an adhesive agent to prevent drainage 
of the drug from the nasal cavity to the mouth. The 
drug was then administered to the nasal cavity through 
the tube by means of a syringe. Blood was sampled 
periodically from the femoral aorta. Unchanged radi 
olabelled naloxone was analyzed according to the pro 
cedure described by Fishman et al, J. Pharmacol. Exp. 
Ther. 187, 575-580 (1973). The method involved cen 
trifugation of the blood and spiking the plasma samples 
with cold naloxone. The drug was then extracted from 
the plasma with ethyl acetate. The ethyl acetate extract 
was then spotted onto thin layer chromatographic 
plates and the plates were developed in a 100:60:2 chlo 
roform-methanol-acetic acid system (parts by volume). 
The zone corresponding to free naloxone visualized by 
ultraviolet absorption was removed and the radioactiv 
ity counted. 
TABLE I below shows the individual plasma level 
data of naloxone from intravenous (PART A), nasal 
(PART B) and oral (PART C) routes, while the ?gure 
of drawing shows the mean plasma levels of naloxone 
for the different routes of administration. TABLE II 
below shows the area under the curve values (AUC 0) 
for the individual rats for each of the three routes of 
administration, the bioavailability calculated for the 
nasal and oral routes, and the half-lives of elimination of 
the drug after intravenous and nasal administration. 
TABLE I 
Plasma Level (nglml! 
Time 
(Min.) 1 II III Mean SE 
PLASMA LEVELS OF NALOXONE AFTER INTRA 
VENOUS ADMINISTRATION OF 30 lag/RAT (4O “Ci/RAT) 
OF 3I*I—NALOXONE IN INDIVIDUAL RATS 
1 101.65 91.45 138.57 110.56 14.31 
3 52.28 44.00 77.77 58.02 10.16 
5 31.38 33.03 47.93 37.45 5.26 
10 15.60 16.92 26.34 19.62 3.38 
20 10.27 11.44 13.01 11.57 0.79 
30 7.28 9.16 8.59 8.34 0.56 
45 5.47 7.98 6.77 6.74 0.72 
60 4.87 5.82 5.54 5.41 0.28 
90 3.01 4.63 4.23 3.96 0.49 
120 2.15 3.87 2.57 2.86 0.52 
180 1.25 1.77 1.40 1.47 0.15 
PLASMA LEVELS OF NALOXONE AFTER NASAL 
ADMINISTRATION OF 30 ug/RAT (40 pCi/RAT) OF 
3I-I—NALOXONI£ IN INDIVIDUAL RATS 
1 36.20 12.71 20.97 23.29 6.88 
3 41.21 30.85 42.80 38.29 3.75 
5 54.45 33.41 44.15 44.00 6.07 
10 45.30 31.53 31.02 35.95 4.68 
20 22.73 17.68 17.99 19.47 1.63 
30 13.46 11.83 10.79 12.03 0.78 
45 9.36 7.95 6.56 7.96 0.81 
60 8.26 5.98 4.98 6.41 0.97 
90 4.79 3.16 2.80 3.58 0.61 
120 3.65 2.29 1.84 2.59 0.54 ' 
180 1.95 1.22 1.10 1.42 0.27 
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TABLE I ' 
(PART C) 
PLASMA LEVELS OF NALOXONE AFTER ORAL 
ADMINISTRATION OF 30 pg/RAT (40 uCi/RAT) OF 3H 
NALOXONE IN INDIVIDUAL RATS 
Time Plasma Level (ng/ml) 
(Min.) 1 II III Mean SE 
1 0.22 0.10 1.43 0.25 0.10 
3 0.44 0.15 0.74 0.44 0.30 
5 0.18 0.30 0.64 0.37 0.24 
10 0.22 0.15 0.64 0.34 0.15 
20 0.19 0.03 0.25 0.16 0.11 
30 0.28 0.10 0.17 ' 0.18 0.09 
45 0.13 0.05 0.16 0.11 0.06 
60 0.10 0.02 0.14 0.09 0.06 
90 0.04 0.03 0. 12 0.06 0.05 
120 ‘ 0.03 0.06 0.10 0.06 0.04 
180 0.03 0.02 0.07 0.04 0.03 
TABLE 11 
AREA UNDER THE BLOOD LEVEL CURVE VALUES 
(AUC ‘0) FOR INDIVIDUAL RATS FROM THE THREE 
ROUTES OF ADMINISTRATION OF NALOXONE AND 
HALF-LIVES 0F ELIMINATION OF NALOXONE 
FOLLOWING INTRAVENOUS AND NASAL 
ADMINISTRATION 
1 11 111 Mean SE 11 
IV 1269.7 1540.5 1685.8 1498.7 121.9 59.2 min. 
Nasal 1904.2 1336.2 1312.0 1517.5 193.5 52.1 min. 
Oral 19.1 11.3 35.5 22.0 7.1 - 
BIOAVAILABILITY CALCULATIONS: 
AUC nasal 
Wx 100 = 1.013 X 100 = 101.3% 
AM 
AUC iv >< 100 = 0.015 x 100 = 1.5% 
It can be seen from TABLE II that the areas undei 
the curve following intravenous and nasal administra‘ 
tion were not signi?cantly different, i.e. absorption 01 
naloxone via the nasal route of administration was as 
effective as via the intravenous route. On the othe1 
hand, oral administration of 30 pg of naloxone resulted 
in bioavailability equal to only 1.5% that of the same 
dose given intravenously. Also from TABLE II, it can 
be seen that the nasal bioavailability of naloxone was 
nearly 70 times greater than the oral bioavailability. 
It also can be seen from TABLE I and the FIGURE 
of drawing that naloxone was very rapidly absorbed 
from the nasal mucosa; thus, at the 30 1.1g dosage level, 
the peak plasma level was attained in about 5 minutes 
after instillation of the nose drops. Further, the half-life 
of elimination of the drug after nasal administration was 
found to be comparable to its half-life following intrave 
nous nasal administration. 
The study described above indicates that naloxone is 
rapidly absorbed from the nasal mucosa into the sys 
temic circulation without extensive intestinal or ?rst 
pass metabolism. It is further apparent from this study 
that the bioavailability of naloxone when administered 
nasally is equivalent to the bioavailability of the drug 
when administered intravenously and vastly superior to 
its bioavailability by the oral route. As the phenolic 
hydroxyl group in naloxone is believed to be responsi 
ble for the extensive metabolism seen when the drug is 
administered orally and, consequently, for the drug’s 
poor oral bioavailability, it follows that similar im 
provement in bioavailability for nasal versus oral ad 
ministration will be observed in the case of the other 
phenolic drugs intended for use in the method and com 
positions of the present invention. 
4,464,378 
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Any of the selected drugs intended for use in the 
present invention, i.e. morphine, THC or one of their 
pharmacologically active phenolic analogues, can be 
administered nasally to warm-blooded animals, conve 
niently by formulation into a nasal dosage form com 
prising the desired drug, in a therapeutically effective 
amount (i.e., depending on the selected drug, an anal 
gesically effective amount, an antiemetic effective 
amount, an amount effective to antagonize the effects of 
a narcotic agent, etc.), together with a nontoxic phar 
maceutically acceptable nasal carrier therefor. This 
type of composition can be used in the treatment of any 
of the variety of conditions which are responsive to 
treatment with the selected drug itself by other routes 
of administration. 
As indicated earlier, in the compositions of the inven 
tion, the drug can be employed in the form of the free 
base or, in the case of morphine and its analogues, in the 
form of a pharmaceutically acceptable salt thereof. 
Suitable nontoxic pharmaceutically acceptable nasal 
carriers will be apparent to those skilled in the‘ art of 
nasal pharmaceutical formulations. For those not skilled 
in the art, reference is made to the text entitled “REM 
INGTON’s PHARMACEUTICAL SCIENCES”, 
14th, edition, 1970. Obviously, the choice of suitable 
carriers will depend on the exact nature of the particu 
lar nasal dosage ‘form desired, e.g., whether the drug is 
to be formulated into a nasal solution (for use as drops 
or as a spray), a nasal suspension, a nasal ointment or a 
nasal gel. Preferred nasal dosage forms are solutions, 
suspensions and gels, which contain a major amount of 
water (preferably puri?ed water) in addition to the 
active ingredient. Minor amounts of other ingredients 
such'as pH adjusters (e.g., a base such as NaOH), emul 
si?ers or dispersing agents, buffering agents, preserva 
tives, wetting agents and jelling agents (e.g., methylcel 
lulose) may also be present. Most preferably, the nasal 
composition is isotonic,’ is. it has the same osmotic 
pressure as blood serum. If desired, sustained release 
nasal compositions, e.g. sustained release gels, can be 
readily prepared, preferably by employing the desired 
drug in oneof itsi ‘relatively insoluble forms, such as the 
free base or anfinsoluble 'salt. In the case of morphine 
and its analogues§‘when the free base is not suf?ciently 
insoluble for sustained release compositions, or when a 
more highly insoluble form is desired, a long chain 
carboxylic acid salt of the desired drug can be'conve 
niently employed. The carboxylic acid portion of the 
salt preferably contains 10 to 20 carbon atoms. Such 
“salts (e.g. stearates, palmitates etc.) can be readily syn 
thesized, for example, by dissolving the hydrochloride 
salt of the drug in water, then adding the alkali metal 
salt of the desired long chain carboxylic acid (e.g. so 
dium stearate). The corresponding long chain carbox 
ylic acid salt of the drug which precipitates out of the 
solution is removed by ?ltration. Alternatively, equimo 
lar amounts of the free base of the drug and the long 
chain carboxylic acid are combined in methanol. That 
mixture is then added to a small volume of water, caus 
ing the desired salt (e.g. stearate) of the drug to precipi 
tate out. 
Examples of the preparation of typical nasal composi 
tions containing selected drugs are set forth below. 
However, it is to be understood that these examples are 
given by way of illustration only and are not to be con 
strued as limiting the invention either in spirit or in 
scope as many modi?cations both in materials and in 
methods will be apparent to those skilled in the art. 
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EXAMPLE 1 
l Gram of naloxone hydrochloride is dissolved in 80 
ml of distilled water and the pH of the resultant solution 
is adjusted to 7.4 with dilute sodium hydroxide solution. 
A quantity of water sufficient to bring the total volume 
to 100 ml is then added and suf?cient sodium chloride 
(or other appropriate salt) is added to adjust the solution 
to isotonicity. The solution is then sterilized by being 
passed through a 0.2 micron Millipore ?lter. The ?nal 
composition contains 1 mg of naloxone hydrochloride 
per 0.1 mlof solution. . 
The above procedure is repeated using 1 gram of 
levallorphan tartrate in place of the naloxone hydro 
chloride. The resultant composition contains 1 mg of 
lavallorphan tartrate per 0.1 ml of solution. 
Repetition of the procedure of the ?rst paragraph of 
this example using 5 grams of apomorphine hydrochlo 
ride, 3 grams of hydromorphone hydrochloride, 4 
grams of metopon hydrochloride, 1.5 grams of oxymor 
phone hydrochloride, 0.6 grams of buprenorphine hy 
drochloride, 2 grams of butorphanol tartrate, 3 grams of 
pentazocine hydrochloride, 3 grams of phenazocine 
hydrobromide or 5 grams of nalorphine hydrochloride 
in place of the naloxone hydrochloride affords a nasal 
composition containing, respectively, 5 mg of apomor 
phine hydrochloride, 3 mg of hydromorphone hydro 
chloride, 4 -mg of metopon hydrochloride, 1.5 mg of 
oxymorphone hydrochloride, 0.6 mg of buprenorphine 
hydrochloride, 2 mg of butorphanol tartrate, 3 mg of 
pentazocine hydrochloride, 3 mg of phenazocine hy 
drobromide, or 5 mg of nalorphine hydrochloride, per 
0.1- ml of solution. 
EXAMPLE 2 
l5 Grams of nalbuphine hydrochloride are combined 
with 80 ml of distilled water and the pH is adjusted to 
4.5 with dilute sodium hydroxide solution. A quantity of 
water suf?cient to bring the total volume to 100 ml is 
then added and suf?cient sodium chloride is added to 
adjust the solution to isotonicity. The solution is then 
sterilized by being passed through a 0.2 micron Mil 
lipore ?lter. The resultant composition contains 15 mg 
of nalbuphine hydrochloride per 0.1 ml. 
The procedure described above is substantially re 
peated, except that 15 grams of morphine sulfate are 
used in place of the nalbuphine hydrochloride, afford 
ing a nasal composition containing 15 mg of morphine 
sulfate per 0.1 ml. ' 
Repetitionv of the procedure of the ?rst paragraph of 
this example using 20 grams of pentazocine lactate in 
place of the nalbuphine hydrochloride affords a nasal 
composition containing 20 mg of pentazocine lactate 
per ‘0.1 ml. 
EXAMPLE 3 
l Gram of naltrexone is dissolved in 80 ml of isotonic 
saline solution and the pH of the resultant solution is 
adjusted to 7.0-7.2 with dilute hydrochloric acid. A 
quantity of isotonic saline suf?cient to bring the total 
volume to 100 ml is then added, and the solution, is 
sterilized by being passed through a 0.2 micron Mil 
lipore ?lter. The resultant composition contains 1 mg of 
naltrexone per 0.1 ml. 
Repetition of the foregoing procedure utilizing 0.5 
gram of levonantradol in place of the naltrexone affords 
a nasal composition containing 0.5 mg of levonantradol 
per 0.1 ml. 
4,464,378 
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The procedure of the ?rst paragraph of this example 
is substantially repeated, save that 4 grams of butor 
phanol are employed in place of the naltrexone, to af 
ford a nasal composition containing 4 mg of butor 
phanol per 0.1 ml. 
Substitution of 2 grams of cyclazocine for the naltrex 
one used in the ?rst paragraph of this example and 
substantial repetition of the procedure there detailed 
afford a nasal composition containing 2 mg of cyclazo 
cine per 0.1 ml. 
EXAMPLE 4 
80 Grams of water are heated to 80° C. and 3.0 grams 
of Methocel are added, with stirring. The resultant 
mixture is allowed to stand at room temperature for 3 
hours. Then, 1.5 grams of naloxone stearate are sus 
pended in 20 grams of water, that suspension is added to 
the gel and thoroughly mixed, and the resultant viscous 
solution or gel is adjusted to isotonicity with sodium 
chloride. The sustained release composition thus ob 
tained contains 1.5 mg of naloxone stearate per 0.1 ml. 
The above procedure is substantially repeated, except 
that 2.0 rather than 3.0 grams of Methocel are em 
ployed, and 1.5 grams of naltrexone myristate are substi 
tuted for the naloxone stearate. The sustained release 
composition prepared in this manner contains 1.5 mg of 
naltrexone myristate per 0.1 ml. 
Repetition of the procedure of the ?rst paragraph of 
this example, but using 20 grams of nalbuphine palmi 
tate in place of the naloxone stearate, affords a sustained 
release composition containing 20 mg of nalbuphine 
palmitate per 0.1 ml. 
The procedure of the ?rst paragraph of this example 
is substantially repeated, except that 3 grams of levor 
phanol stearate are employed in place of the naloxone 
stearate. The resultant sustained release composition 
contains 3 mg of levorphanol stearate per 0.1 ml. 
Substitution of 4 grams of buprenorphine stearate for 
the naloxone stearate used in the ?rst paragraph of this 
example and substantial repetition of the procedure 
there detailed afford a sustained release composition 
containing 4 mg of buprenorphine stearate per 0.1 ml. 
In a similar manner, repetition of the procedure of the 
?rst paragraph of this example, but using 2.5 grams of 
butorphanol palmitate, 3.5 grams of pentazocine myris 
tate, 10 grams of THC, 20 grams of GED or 1 gram of 
levonantradol in place of the naloxone stearate affords a 
sustained release composition containing, respectively, 
2.5 mg of butorphanol palmitate, 3.5 mg of pentazocine 
myristate, 10 mg of THC, 20 mg of CBD or 1 mg of 
levonantradol, per 0.1 ml. 
EXAMPLE 5 
The following are illustrative aqueous solutions of 
selected drugs suitable for use as nasal drops or nasal 
spray. In each case, the pH of the ?nal composition is 
adjusted to 7.4. If desired, the solutions are adjusted to 
isotonicity. 
COMPOSITION A 
Ingredient Amount 
nalbuphine hydrochloride 1000 mg 
Tween 80 4 mg 
methylcellulose 40 mg 
water, puri?ed 10 ml 
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COMPOSITION B 
Ingredient Amount 
nalorphine hydrobromide 500 mg 
Tween 80 3 m8 
methylcellulose 30 mg 
water, puri?ed 10 ml 
COMPOSITION C 
Ingredient Amount 
buprenorphine hydrochloride 100 mg 
Tween 80 2 mg 
methylcellulose 20 mg 
water, puri?ed 10 ml 
Naturally, the therapeutic dosage range for nasal 
administration of the drugs according to the present 
invention will vary with the size of the patient, the 
condition for which the drug is administered and the 
particular drug employed. Generally, the daily dosage 
will approximate the amounts previously employed for 
IV, IM or SC administration of the particular drug 
involved. Thus, a typical dose of buprenorphine would 
be 4-8 mg per day as a maintenance dose in the treat 
ment of narcotic addicts. The quantity of nasal dosage 
form needed to deliver the desired dose will of course 
depend on the concentration of drug in the composi 
tion. The volume of solution or gel which would be 
needed to deliver the daily dose of buprenorphine speci 
?ed above would be 0.1 to 0.2 ml of 4% solution or gel. 
While the invention has been described in terms of 
various preferred embodiments, the skilled artisan will 
appreciate that various modi?cations, substitutions, 
omissions and additions may be made without departing 
from the spirit thereof. Accordingly, it is intended that 
the scope of the present invention be limited solely by 
the scope of the following claims. 
What is claimed is: 
1. A method for eliciting an analgesic or narcotic 
antagonist response in a warm-blooded animal, which 
comprises nasally administering to said animal: 
(a) to elicit an analgesic response, an analgesically 
effective amount of morphine, hydromorphone, 
metopon, oxymorphone, desomorphine, dihydro 
morphine, levorphanol, cyclazocine, phenazocine, 
levallorphan, 3-hydroxy-N-methylmorphinan, 
levophenacylmorphan, metazocine, norlevor 
phanol, phenomorphan, nalorphine, nalbuphine, 
buprenorphine, butorphanol or pentazocine, or a 
nontoxic pharmaceutically acceptable acid addi 
tion salt thereof; or . 
(b) to elicit a narcotic antagonist response, a narcotic 
antagonist effective amount of naloxone, naltrex 
one, diprenorphine, nalmexone, cyprenorphine, 
levallorphan, alazocine, oxilorphan, cyclorphan, 
nalorphine, nalbuphine, buprenorphine, butor 
phanol, cyclazocine or pentazocine, or a nontoxic 
pharmaceutically acceptable acid addition salt 
thereof. 
2. A method according to claim 1 for eliciting a nar 
cotic antagonist response in a warm-blooded animal, 
which comprises nasally administering to said animal a 
narcotic antagonist effective amount of naxolone, nal 
trexone, diprenorphine, nalmexone, cyprenorphine, 
levallorphan, alazocine, oxilorphan, cyclorphan, nalor 
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phine, nalbuphine, buprenorphine, butorphanol, cyclaz 
ocine or pentazocine, or a nontoxic pharmaceutically 
acceptable acid addition salt thereof. 
3. The method according to claim 2 wherein the 
compound administered is naloxone, naltrexone, nalor 
phine, nalbuphine, buprenorphine, diprenorphine, nal 
mexone or cyprenorphine, or a nontoxic pharmaceuti 
cally acceptable acid addition salt thereof. 
4. The method according to claim 2 wherein the 
compound administered is in the form of a long-chain 
carboxylic acid salt, the carboxylic acid portion of the 
salt containing from 10 to 20 carbon atoms. 
5. The method according to claim 4 wherein the long 
chain carboxylic acid salt is a stearate, palmitate or 
myristate. , ‘ 
6. The method according to claim 3 wherein the 
compoundadministered is naloxone or a nontoxic phar 
maceutically acceptable acid addition salt thereof. 
7. The method according to claim 3 wherein the 
compound administered is naltrexone or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
8. The method according to claim 3 wherein the 
compound administered is nalorphine or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
9. The method according to claim .3 wherein the 
compound administered is nalbuphine or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
10. The methodv according to claim 3 wherein the 
compound administered is buprenorphine or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
11. A method according‘to claim 1 for. eliciting an 
analgesic response in, a warm-blooded animal which 
comprises nasally administering to said animal 'an anal 
gesically effective'amount of ~ nalorphine, nalbuphine, 
buprenorphine, butorphanol, cyclazocine, levallorpha'n 
or pentazocine, or a-nontoxic pharmaceutically accept 
able acid addition salt thereof. ' 
12. The method according to claim 11 wherein the 
compound administered is in the form of a long chain 
carboxylic acid salt, the carboxylic acid portion of the 
salt containing from 10 to 20 carbon atoms. 
13. The method according to claim‘ 12 wherein the 
long chain carboxylic acid salt is a stearate, palmitate or 
myristate. ' 
14. The method according to claim 11 wherein the 
compound administered is buprenorphine or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
15. A method according to claim 1 for eliciting an 
analgesic response in a warm-blooded animal, which 
comprises nasally administering to said animal an anal 
gesically effective amount of morphine, hydromor 
phone, metopon, oxymorphone, desomorphine, dihy 
dromorphine, levorphanol, phenazocine, 3-hydroxy-N 
methylrnorphinan, levophenacylmorphan, metazocine, 
norlevorphanol or phenormorphan, or a nontoxic phar 
maceutically acceptable acid addition salt thereof. 
16. The method according to claim 15 wherein mor 
phine is administered, in the form of the free base or a 
nontoxic pharmaceutically acceptable acid addition salt 
thereof. - 
17. The method according to claim 15 wherein hy 
dromorphone, metopon, oxymorphone, desomorphine, 
dihydromorphine, levorphanol, phenazocine, 3 
hydroxy-N-methylmorphinan, levophenacylmorphan, 
metazocine, norlevorphanol or phenomorphan is ad 
ministered, in the form of the free base or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
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18. The method according to claim. 17 wherein the 
compound administered is hydromorphone, metopon or 
oxymorphone, or a nontoxic pharmaceutically accept 
able acid addition salt thereof. ‘ 
19. The method according to claim 15 wherein the 
compound administered is in the form of a long chain 
carboxylic acid salt, the carboxylic acid portion of the 
salt containing from 10 to 20 carbon atoms. 
20. A method according to claim 2 wherein the com 
pound administered is butorphanol, pentazocine, cy 
clazocine or oxilorphan, or a nontoxic pharmaceutically 
acceptable acid addition salt thereof. . I 
21. The method according to claim 20 wherein the 
compound administered is butorphanol or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
22. A method according to claim 11 wherein the 
compound administered is butorphanol, cyclazocine or 
pentazocine, or a nontoxic pharmaceutically acceptable 
acid addition salt thereof. 
23. The method according to claim 17 wherein the 
compound administered is levorphanol or a nontoxic 
pharmaceutically acceptable acid addition salt thereof. 
24. The method according to claim 1 wherein the 
compound administered is morphine, oxymorphone, 
buprenorphine, naloxone, nalorphine, nalbuphine, nal 
,trexone, hydromorphone, metopon, nalmexone, cy 
prenorphine or diprenorphine, or a nontoxic pharma 
ceutically acceptable acid addition salt thereof. 
25. The method according to claim 24 wherein the 
compound is in the form of a long-chain carboxylic acid 
salt, the carboxylic acid portion of the salt containing 
from 10 to 20 carbon atoms. 
26. The method according to claim 25 wherein the 
long-chain carboxylic acid salt is a stearate, palmitate or 
, I myristate. 
27. The method according to claim l-wherein the 
_' compound administered is levorphanol, cyclazocine, 
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phenazocine, butorphanol, pentazocine or oxilorphan, 
or a nontoxic pharmaceutically acceptable acid addition 
salt'thereof. 
28. The method according to claim 27 wherein the 
compound is in the form of a long-chain carboxylic acid 
salt, the carboxylic acid portion of the salt containing 
from 10 to 20 carbon atoms. _ 
29. The method according to claim 28 wherein the 
long-chain carboxylic acid salt is a stearate, palmitate or 
myristate. 
30. A pharmaceutically acceptable nasal dosage form 
for eliciting an analgesic response in a warm-blooded 
animal, which comprises (i) an analgesically effective 
amount of morphine, hydromorphone, metopon, oxy 
morphone, desomorphine, dihydromorphine, levorpha 
nol, cyclazocine, phenazocine, 3-hydroxy-N-methyl 
morphinan, levophenacylmorphan, metazocine, nor 
levorphanol, phenomorphan, nalorphine, nalbuphine, 
buprenorphine, butorphanol, levallorphan or pentazo 
cine, or a nontoxic pharmaceutically acceptable acid 
addition salt thereof, and (ii) a nontoxic pharmaceuti 
cally acceptable nasal carrier therefor, said nasal dosage 
form comprising a nasal ointment or a nasal gel. 
31. A dosage form according to claim 30, said dosage 
form comprising a nasal ointment. 
32. A dosage form according to claim 30, said dosage 
form comprising a nasal gel. 
33. A dosage form according to claim 32, said dosage 
form comprising a sustained release nasal gel. 
34. A dosage form according to claim 30, wherein (i) 
comprises an analgesically effective amount of mor 
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phine or buprenorphine, or of a nontoxic pharmaceuti 
cally acceptable acid addition salt of morphine or bu 
prenorphine. 
35. A dosage form according to claim 30, wherein the 
compound administered is in the form of a long chain 
carboxylic acid salt, the carboxylic acid portion of the 
salt containing from 10 to 20 carbon atoms. 
36. A pharmaceutically acceptable nasal dosage form 
for eliciting a narcotic antagonist response in a warm 
blooded animal, which comprises (i) a narcotic antago 
nist effective amount of naloxone, naltrexone, diprenor 
phine, nalmexone, cyprenorphine, levallorphan, alazo 
cine, oxilorphan, cyclorphan, nalorphine, nalbuphine, 
buprenorphine, butorphanol, cyclazocine or pentazo 
cine, or a nontoxic pharmaceutically acceptable acid 
addition salt thereof, and (ii) a nontoxic pharmaceuti 
cally acceptable nasal carrier therefor, said nasal dosage 
form comprising a nasal ointment or a nasal gel. 
37. A dosage form according to claim 36, said dosage 
form comprising a nasal ointment. 
38. A dosage form according to claim 36, said dosage 
form comprising a nasal gel. 
39. A dosage form according to claim 38, said dosage 
form comprising a sustained release nasal gel. 
40. A dosage form according to claim 36, wherein (i) 
comprises a narcotic antagonist effective amount of 
naloxone, naltrexone, nalorphine, nalbuphine or bu 
prenorphine, or of a nontoxic pharmaceutically accept 
able acid addition salt of naloxone, naltrexone, nalor 
phine, nalbuphine or buprenorphine. 
41. A dosage form according to claim 36, wherein the 
compound administered is in the form of a long chain 
carboxylic acid salt, the carboxylic acid portion of the 
salt containing from 10 to 20 carbon atoms. 
42. A pharmaceutically acceptable sustained release 
nasal dosage form for nasally delivering systemic thera~ 
peutic levels of drug to a warm~blooded animal which 
comprises (i) a systemically therapeutically effective 
amount of a long chain carboxylic acid salt of morphine, 
hydromorphone, metopon, oxymorphone, desomor 
phine, dihydromorphine, levorphanol, cyclazocine, 
phenazocine, 3-hydroxy-N-methylmorphinan, levo~ 
phenacylmorphan, metazocine, norlevorphanol, pheno 
morphan, nalorphine, nalbuphine, buprenorphine, 
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butorphanol, pentazocine, naloxone, naltrexone, dipren 
orphine, nalmexone, cyprenorphine, levallorphan, 
alazocine, oxilorphan or cyclorphan, and (ii) a nontoxic 
pharmaceutically acceptable nasal carrier therefor. 
43. A dosage form according to claim 42, wherein (i) 
comprises a systemically therapeutically effective 
amount of a long chain carboxylic acid salt of naloxone, 
naltrexone, nalorphine, nalbuphine or buprenorphine. 
44. A dosage form according to claim 42, wherein the 
carboxylic acid portion of said salt contains 10 to 20 
carbon atoms. 
45. A dosage form according to claim 44, wherein 
said salt is a stearate, palmitate or myristate. 
46. A dosage form according to claim 42, said dosage 
form comprising a nasal solution, nasal suspension, nasal 
ointment or nasal gel. 
47. A dosage form according to claim 42, wherein (i) 
comprises a systemically therapeutically effective 
amount of a long chain carboxylic acid salt of levorpha 
nol, cyclazocine, phenazocine, butorphanol, pentazo 
cine or oxilorphan. 
48. A method for eliciting an analgesic response in a 
warm-blooded animal, which comprises nasally admin 
istering to said animal an analgesically effective amount 
of a pharmaceutically acceptable nasal dosage form as 
claimed in claim 30. 
49. A method for eliciting a narcotic antagonist re 
sponse in a warm-blooded animal, which comprises 
nasally administering to said animal a narcotic antago 
nist effective amount of a pharmaceutically acceptable 
nasal dosage form as claimed in claim 36. 
50. A dosage form according to claim 36, wherein (i) 
comprises a narcotic antagonist effective amount of 
butorphanol, pentazocine, cyclazocine or oxilorphan, 
or of a nontoxic pharmaceutically acceptable acid addi 
tion salt of butorphanol, pentazocine, cyclazocine or 
oxilorphan. , 
51. A dosage form according to claim 30, wherein (i) 
comprises an analgesically effective amount of levor 
phanol, cyclazocine, phenazocine, butorphanol or pen 
tazocine, or of a nontoxic pharmaceutically acceptable 
acid addition salt of levorphanol, cyclazocine, phenazo 
cine, butorphanol or pentazocine. 
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